Role of Post-Allogeneic Hematopoietic Stem Cell Transplantation Low-Dose Azacitidine for Prevention of Relapse in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Retrospective Analysis

Relapse after allogeneic hematopoietic stem cell transplantation (HSCT) for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) remains a major cause of treatment failure with associated poor prognosis. Low-dose post-HSCT maintenance azacitidine (AZA) has proved to be beneficial in preventing relapses (de Lima et al. Cancer 2010). Herein, we retrospectively evaluated outcomes of patients (pts) treated with low-dose AZA post-HSCT.

Source: Biology of Blood and Marrow Transplantation - January 24, 2020 Category: Hematology Authors: Naveed Ali, Benjamin Tomlinson, Rushang D. Patel, Leland Metheny, Juan Varela, Folashade Otegbeye, Kirsten M. Boughan, Steven C. Goldstein, Linda K. Baer, Jason Willard Balls, Nausheen Ahmed, Megan Smith, Lauren Brister, Cory Edgar, Megan Marie Nelson, To Tags: 175 Source Type: research